Gain Therapeutics CFO Salvatore Calabrese departs; severance includes pay and equity acceleration

Gain Therapeutics, Inc.

CFO Salvatore Calabrese terminates April 30, 2023; severance includes €249,827 (12 months' salary) and €41,638 bonus.
Unvested equity awards accelerate 100% vesting; options exercisable 12 months after termination.
Additional change-of-control benefits available if triggered before April 30, 2024, less severance paid.
Mutual non-disparagement and cooperation provisions; full release of claims against the company.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Salvatore Calabrese

Chief Financial Officer

GANX · Gain Therapeutics, Inc.

Effective: 2023-04-30
Filed: April 28, 2023, 7:59 PM ET

Mr. Calabrese’s employment terminates effective April 30, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Salvatore Calabrese was terminated as Chief Financial Officer at Gain Therapeutics, Inc..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

Mr. Calabrese’s employment terminates effective April 30, 2023

View on SEC.gov

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-052948

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.